Homepage Top Section2

The Phase III SOLO-1 trial assessed Lynparza as a maintenance treatment for patients with newly-diagnosed and advanced BRCA-mutated (BRCAm) ovarian cancer, who have been in complete or partial

Earlier this month, the company said that Chronocort could not confirm its superiority over conventional treatment in endocrine control over a 24-hour period, which was the primary objective

Revolution Medicines and Warp Drive Bio are biotechnology firms involved in the studying of molecules and mechanisms of nature to discover first or best-in-class drugs. The deal will

The study has achieved the primary endpoint by demonstrating Kadcyla as a single agent significantly reduced the risk of disease recurrence or death compared to Herceptin as an

The regulator’s Oncologic Drugs Advisory Committee voted unanimously recommending approval of CT-P10, a proposed monoclonal antibody (mAb) biosimilar to Rituxan, to treat adult patients in three proposed indications.

Cinfa Biotech, which was founded in 2013, has offices in Munich, Germany and Pamplona, Spain. The company, which is part of Spanish pharma firm Cinfa Group, is engaged

The trial showed that Stelara induced clinical remission in a significantly greater proportion of UC patients at week 8 compared to placebo at both doses studied. Major secondary

Merck’s supplemental application has been approved to expand the use of Gardasil 9, which helps in preventing certain cancers and diseases caused by the nine HPV types covered

As per terms of the deal, Boston Pharmaceuticals purchased global rights to two complementary candidates targeting carbapenem-resistant enterobacteriaceae (CRE) and one candidate targeting Pseudomonas. The  anti-infective drug candidates